Gulden Menderes

Oncology

267 Grant St
Bridgeport, CT 06610

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Journal: British journal of cancer

Published: March 04, 2024

Case report: Robotic lymph node resection off the aortic bifurcation for presumed recurrence management of advanced ovarian cancer.

Case report: Robotic lymph node resection off the aortic bifurcation for presumed recurrence management of advanced ovarian cancer.

Journal: International journal of surgery case reports

Published: October 02, 2022

Primary uterine osteosarcoma arising in a leiomyoma with rapid local recurrence: A case report.

Primary uterine osteosarcoma arising in a leiomyoma with rapid local recurrence: A case report.

Journal: Gynecologic oncology reports

Published: September 28, 2022

Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.

Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.

Journal: Expert review of anticancer therapy

Published: May 09, 2022

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.

Journal: Gynecologic oncology

Published: March 27, 2022

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.

Journal: Gynecologic oncology

Published: March 04, 2022

Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.

Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.

Journal: Gynecologic oncology

Published: February 07, 2022

Robotic interval debulking with radical hysterectomy and partial urinary bladder resection for locally advanced carcinosarcoma of the uterus.

Robotic interval debulking with radical hysterectomy and partial urinary bladder resection for locally advanced carcinosarcoma of the uterus.

Journal: Gynecologic oncology reports

Published: January 31, 2022

Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites.

Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites.

Journal: Gynecologic oncology reports

Published: September 19, 2021

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Journal: British journal of cancer

Published: July 05, 2021

An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva.

An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva.

Journal: Journal of gynecologic oncology

Published: June 29, 2021

A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.

A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.

Journal: Cancer

Published: May 13, 2021

Showing 1-12 of 89

Last Updated: 09/26/2026